The stock of vTv Therapeutics Inc (NASDAQ:VTVT) reached all time low today, Nov, 7 and still has $4.24 target or 14.00% below today’s $4.93 share price. This indicates more downside for the $151.06 million company. This technical setup was reported by Barchart.com. If the $4.24 PT is reached, the company will be worth $21.15 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 29,882 shares traded hands or 21.68% up from the average. vTv Therapeutics Inc (NASDAQ:VTVT) has declined 3.79% since April 5, 2016 and is downtrending. It has underperformed by 5.75% the S&P500.
Analysts await vTv Therapeutics Inc (NASDAQ:VTVT) to report earnings on November, 10. They expect $-0.55 earnings per share, down 12.24% or $0.06 from last year’s $-0.49 per share. After $-0.47 actual earnings per share reported by vTv Therapeutics Inc for the previous quarter, Wall Street now forecasts 17.02% negative EPS growth.
vTv Therapeutics Inc (NASDAQ:VTVT) Ratings Coverage
Out of 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. vTv Therapeutics Inc has been the topic of 3 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The stock of vTv Therapeutics Inc (NASDAQ:VTVT) has “Overweight” rating given on Monday, August 24 by Piper Jaffray. The stock of vTv Therapeutics Inc (NASDAQ:VTVT) earned “Buy” rating by Stifel Nicolaus on Monday, August 24. The company was initiated on Friday, September 4 by Canaccord Genuity.
According to Zacks Investment Research, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.”
More notable recent vTv Therapeutics Inc (NASDAQ:VTVT) news were published by: Businesswire.com which released: “vTv Therapeutics Reports Third Quarter Financial and Operational Results and …” on November 02, 2016, also Businesswire.com with their article: “vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer” published on December 02, 2015, Reuters.com published: “BRIEF-vTv Therapeutics reports Q3 financial and operational results and re…” on November 02, 2016. More interesting news about vTv Therapeutics Inc (NASDAQ:VTVT) were released by: Businesswire.com and their article: “vTv Therapeutics Inc. Announces Pricing of Initial Public Offering” published on July 20, 2015 as well as Businesswire.com‘s news article titled: “vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment …” with publication date: January 21, 2016.
VTVT Company Profile
vTv Therapeutics Inc., incorporated on April 02, 2015, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of orally administered small molecule drug candidates. The Company’s drug candidate for the treatment of Alzheimer’s disease (AD), azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial (the STEADFAST Study) under a Food and Drug Administration (FDA) agreed Special Protocol Assessment (SPA). The Company’s type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial (the AGATA Study), and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.